期刊文献+

总前列腺特异性抗原胶乳免疫比浊法的临床应用价值探讨 被引量:1

An Investigation of the Clinical Application Value of Latex Immunoturbidimetric Method for Total Prostate Specific Antigen
下载PDF
导出
摘要 目的评价在生化分析仪上应用胶乳免疫比浊法检测总前列腺特异性抗原(total prostate specific antigen,TPSA)的临床应用价值。方法对试剂盒的各项性能指标进行验证,留取标本对胶乳免疫比浊法结果与化学发光法测定结果进行比较,并对两种方法结果进行线性回归分析。结果精密度、正确度、线性范围、可报告范围、参考范围验证均符合要求,胶乳免疫比浊法样本结果与化学发光法相比较,相关性R^(2)=0.9769。结论胶乳免疫比浊法检测TPSA与发光法检测TPSA结果相符,可极大降低检测成本,扩大适用人群。 Objective To evaluate the clinical value of latex immunoturbidimetry in the detection of total prostate specific antigen(tPSA)using the biochemical analyzer.Methods We evaluated the performance indicators of the kit and prepared samples to compare the results detected by latex immunoturbidimetric method and chemiluminescence method.Results The precision accuracy,linear range and reportable range all met the requirements.The results of latex immunoturbidimetry were compared with that of chemiluminescence,and the correlation R2 was 0.9769.Conclusion The results of TPSA detected by latex immunoturbidimetry are consistent with those detected by luminescence method.Our study suggests that this method can greatly reduce the testing cost and expand the applicable population.
作者 黄素玲 张美娜 孙淑贤 杨晨敏 王京楠 魏晨玲 HUANG Suling;ZHANG Meina;SUN Shuxian;YANG Chenmin;WANG Jingnan;WEI Chenling(Shijiazhuang Hospital of Traditional Chinese Medicine,Shijiazhuang 050000,China)
机构地区 石家庄市中医院
出处 《标记免疫分析与临床》 CAS 2022年第3期501-505,共5页 Labeled Immunoassays and Clinical Medicine
基金 科技部国家重点研发计划(编号:2019YFF0216502)。
关键词 总前列腺特异性抗原 胶乳免疫比浊法 Total prostate specific antigen Latex immunoturbidimetry
  • 相关文献

参考文献6

二级参考文献61

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 2赫杰,赵平,陈万青.2011中国肿瘤登记年报.北京:军事医学科学出版社,2012.
  • 3Segi M. Cancer mortality for selected sites in 24 countries ( 1950- 57). Sendai, Japan: Department of Public Health, Tohoku Uni- versity of Medicine: 1960.
  • 4Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer, 2010, 127 : 2893-2917.
  • 5Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61 : 69-90.
  • 6Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
  • 7Peyromaure M, Debre B, Mao K, et al. Management of prostate cancer in China: a muhicenter report of 6 institutions. J Urol, 2005, 174: 1794-1797.
  • 8Meany DL, Zhen Z, Sokoll JL, et al.Glycoproteomics for prostate can- cer detection: changes in serum PSA glycosylation patterns [J]. J Proteome Res,2009,8(2) : 1613-1619.
  • 9Hevey D, Pertl M, Thomas K, et al.The relationship between pros- tate cancer knowledge and beliefs and intentions to attend PSA screening among at-risk men [J:. Patient Edu Counsel, 2009, 74 (2):244-249.
  • 10Crevoisier RD, Slimane K, Messai T, et al.Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy [J:. Annals Oncol, 2010,21 (4) : 808-814.

共引文献399

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部